CONTENTS

IMPORTANT NOTICE TO PROSPECTIVE [REDACTED]

This document is issued by the Company solely in connection with the [**REDACTED**] *and the* [**REDACTED**] *and does not constitute an* [**REDACTED**] *to sell or a solicitation of an* [**REDACTED**] *to buy any security other than the* [**REDACTED**] *by this document pursuant to the* [**REDACTED**]. *This document may not be used for the purpose of making, and does not constitute, an* [**REDACTED**] *or invitation in any other jurisdiction or in any other circumstances. No action has been taken to permit a* [**REDACTED**] *of the* [**REDACTED**] *in any jurisdiction other than Hong Kong and no action has been taken to permit the distribution of this document in any jurisdiction other than Hong Kong. The distribution of this document for purposes of a* [**REDACTED**] *and the* [**REDACTED**] *and sale of the* [**REDACTED**] *in other jurisdictions are subject to restrictions and may not be made except as permitted under the applicable securities laws of such jurisdictions pursuant to registration with or authorization by the relevant securities regulatory authorities or an exemption therefrom.*

You should rely only on the information contained in this document to make your [**REDACTED**] *decision. The* [**REDACTED**] *is made solely on the basis of the information contained and the representations made in this document. We have not authorized anyone to provide you with information that is different from what is contained in this document. Any information or representation not contained nor made in this document must not be relied on by you as having been authorized by the Company, the Sole Sponsor,* [**REDACTED**]*, any of our or their respective directors, officers, employees, agents, or representatives of any of them or any other parties involved in the* [**REDACTED**]. *Information contained on our website (**www.biosunpharma.com**) does not form part of this document.*

Page

Expected Timetable iv

Contents vii

Summary 1

Definitions 16

Glossary of Technical Terms 25

Forward-Looking Statements 30

Risk Factors 31

Waivers and Exemption 58

Information about this Document and the [REDACTED] 63

Directors and Parties Involved in the [REDACTED] 67

Corporate Information 72

Industry Overview 74

Regulatory Overview 98

CONTENTS

History, Development and Corporate Structure		112
Business		134
Relationship with Our Single Largest Group of Shareholders		206
Directors and Senior Management		209
Share Capital		224
Substantial Shareholders		228
Financial Information		230
Future Plans and Use of [REDACTED]		253
[REDACTED]		257
Structure of the [REDACTED]		265
How to Apply for [REDACTED]		271
Appendix I	**Accountants' Report**	I-1
Appendix II	**Unaudited [REDACTED] Financial Information**	II-1
Appendix III	**Property Valuation Report**	III-1
Appendix IV	**Taxation and Foreign Exchange**	IV-1
Appendix V	**Summary of Principal Legal and Regulatory Provisions**	V-1
Appendix VI	**Summary of the Articles of Association**	VI-1
Appendix VII	**Statutory and General Information**	VII-1
Appendix VIII	**Documents Delivered to the Registrar of Companies in Hong Kong and Available on Display**	VIII-1